Article: In a Study of Vioxx(R) Published in the New England Journal of Medicine, Vioxx Significantly Reduced the Risk of Serious Gastrointestinal Side Effects By Half Compared to Naproxen.

WEST POINT, Pa., Nov. 22 /PRNewswire/ --

Vioxx(R) (rofecoxib) significantly reduced the risk of serious gastrointestinal side effects by 50 percent compared to the non-steroidal anti-inflammatory drug (NSAID) naproxen and significantly reduced the risk of the most serious of these GI side effects by 60 percent, according to a study(A) published for the first time in this week's The New England Journal of Medicine. Merck has submitted the data from this study to the Food and Drug Administration to seek changes to the prescribing information for Vioxx.

The study, called VIGOR (Vioxx Gastrointestinal Outcomes Research), compared Vioxx 50 mg once daily -- a ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!